文献速递神经肿瘤

临床前药物筛选发现托泊替康、放线菌素D和volasertib是ETMR脑肿瘤患者的潜在新治疗候选药物

Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients.
PubMed 文献 · Neuro Oncol · 2017-01-01

该研究针对多层菊形团胚胎性肿瘤(ETMR)开展体外和体内药物筛选,使用BT183细胞系、异种移植模型及首个ETMR患者来源异种移植(PDX)模型。结果显示BT183细胞对托泊替康、多柔比星、地西他滨、帕比司他、放线菌素D及PLK1抑制剂volasertib等敏感;小鼠中托泊替康、volasertib和放线菌素D单药治疗使肿瘤生长暂时缓解并显著延长生存,联合甲氨蝶呤和长春新碱进一步增加肿瘤生长缓解和生存获益。

要点

  • ETMR患者预后极差,诊断后中位生存仅12个月,亟需新治疗方案。
  • 托泊替康、volasertib和放线菌素D单药在异种移植小鼠中使肿瘤生长暂时缓解并显著延长生存。
  • 托泊替康或多柔比星联合甲氨蝶呤和长春新碱较单药进一步增加肿瘤生长缓解和生存获益。

核心结论

  • 研究鉴定出多个有前景的候选药物,可用于ETMR患者未来临床试验的联合治疗。

研究设计与样本

  • 研究使用ETMR细胞系BT183及其异种移植模型进行体外和体内药物筛选。
  • 研究还生成了首个ETMR患者来源异种移植(PDX)模型,并利用该模型在体外药物筛选中评估了主要候选药物。

主要发现

  • BT183细胞对拓扑异构酶抑制剂托泊替康和多柔比星、表观遗传药物地西他滨和帕比司他、放线菌素D以及靶向药物PLK1抑制剂volasertib、极光激酶A抑制剂alisertib和mTOR抑制剂MLN0128非常敏感。
  • 在异种移植小鼠中,托泊替康、volasertib和放线菌素D单药治疗导致肿瘤生长暂时缓解并显著延长生存。
  • 使用托泊替康或多柔比星联合甲氨蝶呤和长春新碱的多药治疗方案,与接受单药治疗的小鼠相比,肿瘤生长缓解和生存进一步增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Embryonal tumor with multilayered rosettes (ETMR) is a rare and aggressive embryonal brain tumor that solely occurs in infants and young children and has only recently been recognized as a separate brain tumor entity in the World Health Organization classification for CNS tumors. Patients have a very dismal prognosis with a median survival of 12 months upon diagnosis despite aggressive treatment. The aim of this study was to develop novel treatment regimens in a preclinical drug screen in order to inform potentially more active clinical trial protocols. METHODS: We have carried out an in vitro and in vivo drug screen using the ETMR cell line BT183 and its xenograft model. Furthermore, we have generated the first patient-derived xenograft (PDX) model for ETMR and evaluated our top drug candidates in an in vitro drug screen using this model. RESULTS: BT183 cells are very sensitive to the topoisomerase inhibitors topotecan and doxorubicin, to the epigenetic agents decitabine and panobinostat, to actinomycin D, and to targeted drugs such as the polo-like kinase 1 (PLK1) inhibitor volasertib, the aurora kinase A inhibitor alisertib, and the mammalian target of rapamycin (mTOR) inhibitor MLN0128. In xenograft mice, monotherapy with topotecan, volasertib, and actinomycin D led to a temporary response in tumor growth and a significant increase in survival. Finally, using multi-agent treatment regimens of topotecan or doxorubicin combined with methotrexate and vincristine, the response in tumor growth and survival was further increased compared with mice receiving single treatments. CONCLUSIONS: We have identified several promising candidates for combination therapies in future clinical trials for ETMR patients.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Schmidt C, Schubert NA, Brabetz S, et al. Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients. Neuro Oncol. 2017. PMID: 28482026. doi:10.1093/neuonc/nox093

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。